MARKET

MGNX

MGNX

MacroGenics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.35
+0.06
+1.13%
After Hours: 5.35 0 0.00% 16:00 04/08 EDT
OPEN
5.41
PREV CLOSE
5.29
HIGH
5.67
LOW
5.22
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
19.63
52 WEEK LOW
4.040
MARKET CAP
262.85M
P/E (TTM)
-1.6871
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MGNX stock price target is 17.82 with a high estimate of 40.00 and a low estimate of 6.00.

EPS

MGNX News

More
  • ImmunoGen: Tremendous Value In Your Turnaround Stock
  • Seeking Alpha - Article · 03/25 15:32
  • These Greater Washington firms took the biggest dives Monday on Wall Street
  • American City Business Journals · 03/16 23:16
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37
  • Edited Transcript of MGNX earnings conference call or presentation 25-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/10 06:50

Industry

Biotechnology & Medical Research
+3.08%
Pharmaceuticals & Medical Research
+2.83%

Hot Stocks

Symbol
Price
%Change

About MGNX

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
More

Webull offers kinds of MacroGenics Inc stock information, including NASDAQ:MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions.